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 ❚ ABSTRACT
Objective: To examine the impact of hypertension on cardiovascular health in patients with 
symptomatic peripheral artery disease and to identify factors associated with uncontrolled 
hypertension. Methods: A cross-sectional study including 251 patients with symptomatic 
peripheral artery disease (63.9% males, mean  age  67±10 years). Following hypertension 
diagnosis, blood pressure was measured to determine control of hypertension. Arterial stiffness 
(carotid-femoral pulse wave velocity) and cardiac autonomic modulation (sympathovagal 
balance) were assessed. Results: Hypertension was associated with higher carotid-femoral 
pulse wave velocity, regardless of sex, age, ankle-brachial index, body mass index, walking 
capacity, heart rate, or comorbidities (ß=2.59±0.76m/s, b=0.318, p=0.003). Patients with 
systolic blood pressure ≥120mmHg had higher carotid-femoral pulse wave velocity values 
than normotensive individuals, and hypertensive patients with systolic blood pressure 
of ≤119mmHg (normotensive: 7.6±2.4m/s=≤119mmHg: 8.1±2.2m/s 120-129mmHg: 
9.8±2.6m/s=≥130mmHg: 9.9±2.9m/s, p<0.005). Sympathovagal balance was not associated 
with hypertension (p>0.05). Conclusion: Hypertensive patients with symptomatic peripheral artery 
disease have increased arterial stiffness. Arterial stiffness is even greater in patients with uncontrolled 
high blood pressure.
Keywords: Intermittent claudication; Peripheral arterial disease; Comorbidity; Cardiovascular 
system; Vascular stiffness; Hypertension
 ❚ RESUMO
Objetivo: Analisar a influência da hipertensão na saúde cardiovascular em pacientes com doença 
arterial periférica sintomática, e identificar fatores associados à hipertensão arterial não controlada. 
Métodos: Neste estudo transversal foram incluídos 251 pacientes com doença arterial periférica 
(63,9% homens e média de idade 67±10 anos). Hipertensão foi diagnosticada e pressão arterial 
foi avaliada para determinar o controle da hipertensão. Foram avaliadas rigidez arterial (velocidade 
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da onda de pulso carótida-femoral) e modulação autonômica 
cardíaca (balanço simpatovagal). Resultados: Hipertensão foi 
associada com maior velocidade da onda de pulso carótida-femoral, 
independentemente do sexo, idade, índice tornozelo-braço, índice de 
massa corpórea, capacidade de deambulação, frequência cardíaca, 
ou comorbidades (ß=2,59±0,76m/s, b=0,318, p=0,003). Pacientes 
com pressão arterial sistólica ≥120mmHg tiveram maior velocidade 
da onda de pulso carótida-femoral do que normotensos, e pacientes 
hipertensos com pressão arterial sistólica ≤119mmHg (normotensos: 
7,6±2,4m/s=≤119mmHg: 8,1±2,2m/s 120-129mmHg: 9,8±2,6m/
s=≥130mmHg: 9,9±2,9m/s, p<0,005). Balanço simpatovagal 
não foi associado à hipertensão. Conclusão: Pacientes hipertensos 
com doença arterial periférica sintomática apresentam maior rigidez 
arterial. Em pacientes com pressão arterial não controlada, a rigidez 
arterial é ainda mais elevada.
Descritores: Claudicação intermitente; Doença arterial periférica; 
Comorbidade; Sistema cardiovascular; Rigidez vascular; Hipertensão
 ❚ INTRODUCTION
Peripheral artery disease (PAD) affects more than 
200 million people worldwide.(1) Hypertension is one 
of the most prevalent risk factors for PAD, affecting 
approximately 80% of patients.(2-4) It is directly related 
to fatal and nonfatal cardiovascular events in this 
patient population.(5) 
Blood pressure control (i.e., systolic blood pressure 
<140mmHg and diastolic blood pressure <90mmHg) 
is thought to be a cornerstone of hypertension 
management.(6) In fact, a prior study(7) showed that 
blood pressure control can decrease the incidence of 
cardiovascular disease and overall mortality by 33% 
(from 3.85% to 2.59% per year) and 32% (from 2.63% 
to 1.78% per year), respectively. However, associations 
between hypertension control and cardiovascular 
function in patients with PAD remain to be determined.
Deeper understanding of the impact of controlled 
and uncontrolled hypertension on cardiovascular 
health may assist physicians in managing cardiovascular 
health, with potential contributions to the survival of 
patients with PAD. Factors associated with uncontrolled 
hypertension in patients with PAD are worthy of 
investigation. 
 ❚ OBJECTIVES 
To examine the impact of hypertension on cardiovascular 
health in patients with symptomatic peripheral artery 




This cross-sectional study followed (Strengthening the 
Reporting of Observational studies in Epidemiology 
(STROBE) checklist.(8) Patients with PAD were 
recruited from vascular units in São Paulo, SP, Brazil. 
Inclusion criteria were patients aged 40 to 90 years 
with symptomatic PAD (ankle-brachial index ≤0.90) in 
one or both legs, absence of critical limb ischemia, rest 
pain, noncompressible vessels, no limb amputation, or 
ulcers. Compliance with study criteria was checked by 
preliminary evaluations.
This study was approved by the Human Research 
Ethics Committees of Hospital das Clínicas, Faculdade 
de Medicina, Universidade de São Paulo (HCFMUSP), 
protocol 3.986.124, CAAE: 42379015.3.3002.0068 and 
of Hospital Albert Einstein (HIAE), protocol 3.959.548, 
CAAE: 42379015.3.0000.0071. Patients were duly 
informed of study risks and benefits and gave their 
written informed consent for participation. Data 
collection was performed between September 2015 and 
December 2017. 
Cardiovascular measurements
Measurements were made in a quiet environment. 
Blood pressure and arterial stiffness were measured 
with patients in the seated and the supine position, 
respectively. Patients were instructed to avoid moderate 
to vigorous physical activity for a minimum of 24 
hours prior to the visit, and to avoid smoking, alcohol 
and caffeine intake for a minimum of 12 hours prior 
to measurements. Data were collected by blinded 
investigators.
Hypertension (predictors)
Patients taking antihypertensive drugs and with systolic 
blood pressure ≥140mmHg or diastolic pressure 
≥90mmHg were defined as hypertensive. Blood pressure 
was measured in both arms using an automatic device 
HEM-742-E (Omron Corporation, Kyoto, Japan). 
Three consecutive blood pressure readings were taken at 
one-minute intervals, as described elsewhere.(9) Higher 
readings were used in the analysis. Patients systolic 
blood pressure <140mmHg and diastolic blood pressure 
<90mmHg were allocated to the controlled group. 
Patients with blood pressure values higher than those 
established for the controlled group were allocated 
to the uncontrolled group.(6) Intraclass correlation 
coefficient for systolic and diastolic blood pressure was 
0.85 and 0.92, respectively.(10)
Arterial stiffness (outcome)
Carotid–femoral pulse wave velocity (cfPWV) was 
used to assess arterial stiffness. Measurements were 
Impact of hypertension on arterial stiffness and cardiac autonomic modulation in patients with peripheral artery disease
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made using a high-fidelity applanation tonometer 
(Sphygmocor, ATCOR Medical, Australia), in compliance 
with Clinical Application of Arterial Stiffness Task 
Force III(11) and American Heart Association Scientific 
Statement: Recommendations for Improving and 
Standardizing Vascular Research on Arterial Stiffness(12) 
guidelines. The intraclass correlation coefficient for 
cfPWV was 0.91.(10)
Cardiac autonomic modulation (outcome)
Cardiac autonomic modulation assessment was based 
on heart rate variability analysis, as per previously 
described procedures.(9) Inter-beat (RR) intervals were 
obtained using a heart rate monitor (V800, Polar® 
Electro, Oulu, Finland); a minimum of five minutes of 
stationary RR interval data were used. Frequency domain 
variables were calculated using the autoregressive 
method. Signals operating at frequencies between 0.04 
and 0.4Hz were considered physiologically significant. 
Low (LF) and high (HF) frequency components were 
represented by oscillations ranging from 0.04 to 0.15Hz 
and 0.15 to 0.4Hz, respectively. The LF/HF ratio was 
defined as the cardiac sympathovagal balance. Analyses 
were performed using Kubios HRV software (Biosignal 
Analysis and Medical Imaging Group, Joensuu, 
Finland). Task Force for Heart Rate Variability 
recommendations were followed.(13)
Covariates
Demographic data (age and sex), ankle-brachial index, 
comorbidities (diabetes, coronary artery disease, heart 
failure, chronic kidney disease, cerebrovascular disease 
and dyslipidemia), walking capacity, heart rate, and body 
mass index were assessed at the beginning of the study, 
using previously described procedures.(9,14) Interarm 
blood pressure differences >10mmHg were considered 
to be indicative of upper extremity PAD.(15)
Statistical analysis
Data normality and homogeneity were checked using the 
Kolmogorov Smirnov and the Levene test respectively. 
For descriptive statistics, continuous variables were 
summarized as mean and standard deviation, whereas 
categorical variables were summarized as relative 
frequency. Linear regression models were used to 
investigate associations between cardiovascular variables 
(arterial stiffness and cardiac autonomic modulation) 
and hypertension. Crude analyses were performed 
first, then adjusted for classical confounding variables. 
Residual analysis was performed and homoscedasticity 
examined using graphical analysis (scatterplots). 
Multicollinearity analysis was conducted assuming 
variance inflation factors of less than than 5, and 
tolerance values of less than 0.20.
One-way ANOVA was used to compare cfPWV 
values between normotensive and hypertensive patients 
(≤119mmHg; 120-129mmHg and ≥130mmHg). Multiple 
logistic regression was used to determine factors 
associated with uncontrolled hypertension in patients 
with PAD. Variables with a p value <0.30 in bivariate 
analysis were included in the model, and only those 
with a p value <0.10 retained in the final model. Model 
goodness-of-fit was assessed using the Hosmer-
Lemeshow test. 
Pearson’s correlation coefficient was used to 
examine the relation between systolic blood pressure 
and cfPWV. The level of significance was set at 5% 
(p<0.05).
 ❚ RESULTS
Out of 261 patients enrolled in this study, 10 were 
excluded due to missing blood pressure data. The final 
sample comprised 251 patients with PAD whose data 
were available for analysis. All patients had moderate 
PAD, and 24.8% had signs suggestive of upper extremity 
PAD. Mean body mass index was 27.4±6.3kg/m². 
Hypertension was diagnosed in 89.6% patients, of 
whom 50.2% had uncontrolled hypertension. Clinical 
characteristics of patients with controlled or uncontrolled 
hypertension are shown in table 1. More frequent use 
of angiotensin-converting enzyme inhibitor (ACE), 
older age, and higher systolic and diastolic blood 
pressure values were more prevalent among patients 
with uncontrolled hypertension relative to patients with 
controlled hypertension (p<0.05) (Table 1). 
Associations between hypertension and cardiovascular 
variables are shown in table 2. Hypertension was 
associated with higher cfPWV, regardless of sex, age, 
ankle-brachial index, body mass index, walking capacity, 
heart rate or comorbidities (p<0.05). Hypertension 
was not associated with cardiac autonomic modulation 
(p>0.05).
Systolic blood pressure, diastolic blood pressure, 
mean blood pressure, heart rate and pulse pressure 
were positively correlated with cfPWV (Figures 1A-1E). 
Patients with PAD and systolic blood pressure 
≥120mmHg had higher cfPWV than normotensive 
or hypertensive patients with systolic blood pressure 
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 ❚ DISCUSSION
In this study, hypertension was associated with greater 
arterial stiffness in patients with PAD, regardless 
of sex, age, ankle-brachial index, body mass index, 
walking capacity, heart rate or comorbidities. Arterial 
stiffness was also greater in hypertensive patients with 
PAD and systolic blood pressure ≥120mmHg than in 
normotensive and hypertensive patients with PAD 
and systolic blood pressure ≤119mmHg. Older age, 
≤119mmHg (normotensive: 7.6±2.4m/s; systolic blood 
pressure ≤119mmHg: 8.1±2.2m/s; systolic blood 
pressure 120-129mmHg: 9.8±2.6m/s; systolic blood 
pressure ≥130mmHg: 9.9±2.9m/s; p<0.005) (Figure 1F). 
Older age, lower ankle-brachial index and no use of 
ACEi were associated with uncontrolled hypertension, 
based on regression analysis (Table 3).
Table 2. Association between hypertension and cardiovascular variables in 
patients with symptomatic peripheral artery disease
Independent variable β(SE)
cfPWV(m/s) LF/HF
β(SE) B β(SE) b
Hypertension (no=0, yes=1) Crude 1.61 (0.66) 0.184* -0.70 (0.39) -0.157
Adjusted 2.37 (0.87) 0.248* 0.13 (0.85) 0.014
* p<0.05. Model for cfPWV: adjusted for sex, age, ankle-brachial index, body mass index, six-minute walk test, heart rate, 
diabetes, obesity, coronary artery disease, stroke and dyslipidemia. Model for LF/HF: adjusted for sex, age, ankle-brachial 
index, body mass index, six-minute walk test, diabetes, obesity, coronary artery disease, stroke, and dyslipidemia. 
cfPWV: carotid-femoral pulse wave velocity; LF: low frequency; HF: sympathovagal balance; SE: standard error; b: standar-
dized beta coefficients.
Table 3. Factors associated with uncontrolled hypertension in patients with 










Age (years) 1.06 (1.02-1.10) 0.061 (0.019) 0.001
Ankle-brachial index 0.14 (0.02-0.88) -1.975 (0.941) 0.036
Use of ACEi (ref=no) 0.38 (0.19-0.76) -0.970 (0.365) 0.008
Dyslipidemia (ref=no) 0.42 (0.16-1.05) -0.878 (0.475) 0.065
Hosmer and Lemeshow test: χ²=7.599; p=0.474.
OR: odds ratio; SE: standard-error; β: regression coefficient; ACEi: angiotensin converting enzyme inhibitor. 
Table 1. Comparison of general characteristics of patients with peripheral artery 
disease and controlled or uncontrolled hypertension 
Variables Controlled hypertension 
Uncontrolled 
hypertension p value
Clinical and demographic variables
Male sex (%) (53.6) (46.4) 0.130
Age (years) 65±10 69±8 0.001
Ankle-brachial index 0.60±0.19 0.57±0.16 0.245
Body mass index (kg/m²) 28.0±4.9 27.4±4.7 0.342
Claudication distance (m) 133±85 125±68 0.465
Six-minute walk test (m) 326±91 318±85 0.531
Systolic blood pressure (mmHg) 121±12 158±15 <0.001
Diastolic blood pressure (mmHg) 69±10 78±10 <0.001
Comorbidities
Current smoker (%) (42.9) (57.1) 0.334
Diabetes (%) (48.4) (51.7) 0.633
Dyslipidemia (%) (53.2) (46.8) 0.056
Obesity (%) (52.6) (47.4) 0.642
Coronary artery disease (%) (55.6) (44.4) 0.241
Stroke (%) (56.1) (43.9) 0.806
Medications
Antiplatelet (51.2) (48.8) 0.949
ACE inhibitor (%) (64.9) (35.1) 0.018
Angiotensin-receptor antagonist (%) (48.4) (51.6) 0.579
Calcium channel blocker (%) (47.5) (52.5) 0.481
Diuretic (%) (45.5) (54.5) 0.152
Beta-blocker (%) (51.6) (48.4) 0.924
Statin (%) (53.2) (46.8) 0.137
Hypoglycemic (%) (47.7) (52.3) 0.371
Peripheral vasodilator (%) (58.5) (41.5) 0.219
ACE inhibitor + diuretic + calcium 
channel blocker (%)
(53.8) (46.2) 0.904
Values expressed as median±interquartile range and frequency. 
ACE: angiotensin conversion enzyme. 
* significantly different from hypertensive patients with systolic blood pressure 120-129mmHg; # significantly different 
from hypertensive patients with systolic blood pressure ≥130mmHg.
BP: blood pressure; cfPWV: carotid–femoral pulse wave velocity.
Figure 1. Correlations between systolic blood pressure (A); diastolic blood 
pressure (B); mean blood pressure (C); pulse pressure (D); heart rate (E) and 
carotid–femoral pulse wave velocity; comparison of arterial stiffness between 
normotensive and hypertensive patients with systolic blood pressure of 
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lower ankle–brachial index, and no use of ACEi were 
associated with uncontrolled hypertension in patients 
with PAD.
Prior studies have shown that hypertension is the 
most prevalent comorbidity in patients with PAD.(2-4) 
This analysis revealed similar findings. The prevalence 
of hypertension was associated with increased arterial 
stiffness, even after adjustment for confounding factors, 
as reported in other studies investigating patients 
with hypertension and diabetes.(16,17) From a clinical 
standpoint, these are relevant findings, since increased 
arterial stiffness is associated with poorer cardiovascular 
outcomes, regardless of traditional risk factors.
Arterial stiffness plays a key role in the 
pathophysiology of hypertension.(18,19) It is also strongly 
related to atherosclerosis development and should, 
therefore, be considered a significant clinical marker in 
patients with PAD.(20,21) The median cfPWV value was 
2.4m/s higher in hypertensive relative to normotensive 
patients with PAD. This implies a higher cardiovascular 
risk, given a 1m/s increase in cfPWV is associated with 
a 14% increase in the odds of having a cardiovascular 
event and a 15% increase in cardiovascular mortality.(22)
Patients with controlled hypertension had lower 
cfPWV values than those with uncontrolled hypertension, 
suggesting interventions aimed to reducing cfPWV may 
benefit patients with PAD. For example, medications 
with proven ability to decrease arterial stiffening, 
particularly ACEi and calcium channel blockers,(23) have 
a positive effect on aortic stiffness. In addition to drug 
treatment, lifestyle modifications, such as physical 
activity, should be recommended to reduce blood pressure.
Sympathovagal balance of 2.0 in patients with PAD 
in this study indicated a shift in cardiac autonomic 
modulation towards increased sympathetic and decreased 
parasympathetic modulation. Similar findings have been 
reported elsewhere.(24,25) Increased sympathetic and 
decreased cardiac parasympathetic modulation are 
thought to be important predictors of fatal and nonfatal 
cardiac events.(26) Data in this study failed to reveal a 
relation between hypertension and sympathovagal 
balance. This may seem odd at first, since patients 
with hypertension have an autonomic dysfunction.(13) 
However, half of patients were taking beta-blockers. 
Beta-blockers upregulate the fractal behavior of cardiac 
autonomic modulation in patients with cardiovascular 
diseases,(27,28) allowing for better cardiovascular control. 
In the current study, advanced age, lower ankle-
brachial index and no use of ACEi, were associated 
with uncontrolled hypertension in patients with PAD. 
Likewise, previous studies revealed lower ankle-brachial 
index, greater impairment of walking capacity,(29) 
poor fitness,(29) low levels of physical activity,(30,31) and 
more barriers to physical activity, in older patients.(3,32) 
These variables are classic predictors of good 
cardiovascular health.(33) Uncontrolled hypertension 
was also more likely among patients who did not use 
ACEi. According to a review study,(34) renin-angiotensin 
system blockers, especially angiotensin converting 
enzyme inhibitor inhibitors, may effectively reduce 
the risk of cardiovascular ischemic events in patients 
with PAD.
Findings of this study have important practical 
implications. For example, systolic blood pressure 
<140mmHg and diastolic blood pressure <90mmHg 
(i.e., controlled blood pressure) are thought to be 
cornerstones of hypertensive patient management.(6) 
Hypertension was associated with increased arterial 
stiffness, regardless of sex, age, ankle-brachial index, 
body mass index, walking capacity, heart rate or 
comorbidities. However, hypertensive patients with 
systolic blood pressure  ≤119mmHg had better vascular 
health (lower arterial stiffness). Therefore, these 
values should be accounted for in the establishment 
of therapeutic goals, as suggested in American 
guidelines,(35) is spite of divergences from Brazilian(6) 
and European guidelines.(36)
This study has limitations. Firstly, cross-sectional 
study design precludes causal inference. Therefore, 
longitudinal studies are warranted to investigate 
mechanisms responsible for the associations detected. 
Secondly, only patients with symptomatic PAD were 
included. Hence, findings cannot be extrapolated 
to patients with other stages of the disease. Thirdly, 
small sample size and the fact that patients were using 
different drugs may have impacted cardiovascular 
variables, and stratified analysis according to type 
of medication was not possible. Finally, biomarkers 
were not measured, which limits the understanding of 
mechanisms underlying the associations reported, as 
well as the extrapolation of findings to other patients.
 ❚ CONCLUSION
Hypertension was associated with increased arterial 
stiffness in patients with PAD. Patients with uncontrolled 
hypertension had greater arterial stiffness. These 
findings underscore the significance of blood pressure 
control in these patients.
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